TICLOPIDINE TREATMENT IN IDIOPATHIC PLASMACYTIC LYMPHADENOPATHY WITH POLYCLONAL HYPERIMMUNOGLOBULINEMIA ACCOMPANIED BY NEPHROTIC SYNDROME

被引：7

作者：

KATO, Y

KOBAYASHI, H

MIHARA, H

MIZUTANI, Y

KAMIJIMA, S

TANAKA, A

TAKEDA, H

KATO, R

OGURI, T

机构：

[1] Second Department of Internal Medicine, Aichi Medical College, Aichi

[2] Second Department of Internal Medicine, Aichi Medical College, Nagakute-cho,Aichi-gun

来源：

INTERNAL MEDICINE | 1992年 / 31卷 / 04期

关键词：

CASTLEMAN LYMPHOMA; FOCAL GLOMERULOSCLEROSIS; RENAL FAILURE;

D O I：

10.2169/internalmedicine.31.504

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 36-year-old woman was admitted for idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia (IPL) associated with nephrotic syndrome. She was expected to lapse into renal failure because renal biopsy showed focal glomerulosclerosis. VEMP chemotherapy and bolus methyl prednisolone were not effective against excessive urine protein of over 10 g/day. We thus began administration of ticlopidine (6 mg/kg/day), prednisolone (0.4 mg/kg/day) and cyclophosphamide (1 mg/kg/day). After 3 months of this regimen, the urine protein level decreased to less than 0.5 g/day, and renal function was maintained for more than 3 years. It is suggested that ticlopidine is effective for nephropathy complications associated with IPL.

引用

页码：504 / 507

页数：4

共 20 条

[1]

Gaba A.R., Stein R.S., Sweet D.L., Variakojis D., Multicentric giant lymph node hyperplasia, Am J Clin Pathol, 69, (1978)

[2]

Mori S., Mouri N., Uchida T., Shimamine T., The cases of idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmuno-globulinemia, Nippon Mounaikei Gakkai Kaishi, 85, (1981)

[3]

Bartoli E., Massarelli G., Soggia G., Tanda F., Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course, Am J Clin Pathol, 73, (1980)

[4]

Frizzera G., Peterson B.A., Bayrd E.D., Goldman A., A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Clinical findings and clinicopathologic correlations in 15 patients, J Clin Oncol, 3, (1985)

[5]

Shimada H., Kanoh T., Uchida H., Matumura K., Multicentric plasma cell type Castleman's lymphadenopathy with nephrotic syndrome, J Jpn Soc Intern Med, 75, (1986)

[6]

Yoshizaki K., Matsuda T., Nishimoto N., Et al., Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease, Blood, 74, (1987)

[7]

Horii Y., Muraguchi A., Iwano M., Et al., Involvement of IL-6 in mesangial proliferative glomerulonephritis, J Immunol, 143, (1989)

[8]

Clement L.T., Grossi C.E., Gartland G.L., Morphologic and phenotypic features of the subpopulation of Leu 2 (+) cells that suppresses B cell differentiation, J Immunol, 133, (1984)

[9]

Churg J., Sobin L.H., Renal disease, Classification and atlas of glomerular disease, (1982)

[10]

Sakai Y., Combination chemotherapy in malignant lymphoma, Saishin-Igaku, 28, (1973)

← 1 2 →